Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Massachusetts Institute of Technology

http://web.mit.edu/

Latest From Massachusetts Institute of Technology

The Runners And Riders In Hidradenitis Suppurativa

Despite its Phase III blow-up, Acelyrin is continuing to back izokibep in the skin disease. But other developers are trying immune agents old and new in what could turn into a billion-dollar market. 

Research & Development Clinical Trials

Biotech IPOs Get Bigger, But Not Necessarily Better

The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.

Companies Financing

Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness

Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.

Stock Watch Financing

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.

Commercial Clinical Trials
See All

Company Information

  • Industry
  • Academic and Research Institutions
  • Other Names / Subsidiaries
    • MIT
UsernamePublicRestriction

Register